STAT Plus: J&J loses patent fight over key prostate cancer drug, teeing up generic competition
MEL EVANS/AP
A U.S. Patent & Trademark Office review board earlier this year had invalidated the same patent after determining it was not sufficiently inventive.
.png)
No hay comentarios:
Publicar un comentario